BELLUS Health To Update on Chronic Cough Drug Candidate

BELLUS Health (TSX:BLU) announced it will host a “Key Opinion Leader” event focused on the treatment of a chronic cough and present an update on their drug candidate.

As quoted in the press release:

The event will feature a presentation by KOL Dr. Jacky Smith, Professor of Respiratory Medicine at the University of Manchester and Director of the NIHR South Manchester Respiratory and Allergy Clinical Research Facility. Dr. Smith will discuss the clinical presentation of chronic cough, its current unmet medical need and therapeutic options as well as novel treatment approaches under development.

Dr. Denis Garceau, BELLUS Health’s Senior Vice President, Drug Development, will also provide an update on BLU-5937, including results from preclinical studies and its development path.

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report

Leave a Reply